FLT3; CDK1; GRK6; CDK6; | |
CA2; CA1; CA12; CA9; CA7; CA4; | |
HPGD; ALOX12; CBR1; AKR1B1; HSD17B10; ALOX15; USP2; UGT1A1; APEX1; | |
KDM4E; | |
TP53; HIF1A; | |
ABCG2; | |
XDH; | |
CREB1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.253E-12 | 4.088E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.365E-11 | 3.219E-08 | CA1, CA12, CA2, CA4, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.493E-11 | 1.027E-07 | CA1, CA12, CA2, CA4, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.281E-11 | 1.064E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.796E-10 | 1.629E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.041E-09 | 1.577E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.530E-07 | 5.553E-05 | CA2, CA9, CDK6, CREB1, CYP1A1, CYP1A2, FLT3, HPGD, TP53, UGT1A1 |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 8.331E-07 | 2.629E-04 | AKR1B1, APEX1, CA2, CA9, CREB1, CYP1A2, FLT3, HPGD, UGT1A1 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 8.994E-07 | 2.758E-04 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.279E-06 | 6.481E-04 | ALOX12, ALOX15, HPGD |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.510E-03 | 7.623E-03 | UGT1A1; AKR1B1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.897E-10 | 1.033E-08 | UGT1A1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.473E-05 | 2.621E-04 | CYP1A2; XDH |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.531E-05 | 3.119E-04 | CYP1A2; CYP1A1; CYP1B1 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.585E-08 | 6.943E-07 | CYP2C9; CBR1; ALOX15; ALOX12; CYP2C19 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.733E-10 | 1.851E-08 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.833E-08 | 7.729E-07 | CYP2C9; UGT1A1; CYP1A2; CYP1A1; CYP3A4 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.247E-13 | 1.322E-11 | CA12; CA1; CA2; CA4; CA7; CA9 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.011E-11 | 7.105E-10 | CYP2C9; CBR1; UGT1A1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.901E-08 | 9.305E-07 | CYP2C9; UGT1A1; CYP1A2; CYP3A4; CYP2C19 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; FLT3; FLT3; CA9; CDK1 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
C00-D49: Neoplasms | Cancer | C00-C96 | TP53; HIF1A; CA1; FLT3; FLT3; CA9; CDK1 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |